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Abstract
Background: Clinical trials comparing thrombectomy devices with conventional percutaneous coronary
interventions (PCI) in patients with acute ST elevation myocardial infarction (STEMI) have produced conflicting
results. The objective of our study was to systematically evaluate currently available data comparing thrombectomy
followed by PCI with conventional PCI alone in patients with acute STEMI.
Methods: Seventeen randomized trials (n = 3,909 patients) of thrombectomy versus PCI were included in this
meta-analysis. We calculated the summary odds ratios for mortality, stroke, post procedural myocardial blush grade
(MBG), thrombolysis in myocardial infarction (TIMI) grade flow, and post procedural ST segment resolution (STR)
using random-effects and fixed-effects models.
Results: There was no difference in risk of 30-day mortality (44/1914 vs. 50/1907, OR 0.84, 95% CI 0.54-1.29,
P = 0.42) among patients randomized to thrombectomy, compared with conventional PCI. Thrombectomy was
associated with a significantly greater likelihood of TIMI 3 flow (1616/1826 vs. 1533/1806, OR 1.41, P = 0.007), MBG
3 (730/1526 vs. 486/1513, OR 2.42, P < 0.001), STR (923/1500 vs. 715/1494, OR 2.30, P < 0.001), and with a higher
risk of stroke (14/1403 vs. 3/1413, OR 2.88, 95% CI 1.06-7.85, P = 0.04). Outcomes differed significantly between
different device classes with a trend towards lower mortality with manual aspiration thrombectomy (MAT) (21/949
vs.36/953, OR 0.59, 95% CI 0.35-1.01, P = 0.05), whereas mechanical devices showed a trend towards higher
mortality (20/416 vs.10/418, OR 2.07, 95% CI 0.95-4.48, P = 0.07).
Conclusions: Thrombectomy devices appear to improve markers of myocardial perfusion in patients undergoing
primary PCI, with no difference in overall 30-day mortality but an increased likelihood of stroke. The clinical benefits
of thrombectomy appear to be influenced by the device type with a trend towards survival benefit with MAT and
worsening outcome with mechanical devices.
Background
Primary percutaneous intervention (PCI) is the preferred
reperfusion modality in patients with ST-elevation myo-
cardial infarction (STEMI) [1]. While primary PCI is
highly effective in achieving epicardial coronary reperfu-
sion, a significant proportion of patients fail to achieve
adequate myocardial reperfusion [2]. Measures of failed
epicardial reperfusion such as persistent ST elevation or
diminished myocardial blush grade (MBG) have demon-
strated consistent association with poor left ventricular
salvage and increased mortality and morbidity [3,4].
Angiographically evident thrombus is a major predictor
of poorer myocardial reperfusion and this is believed to
be secondary to embolization of thrombus and plaque
detritus.
Based on this line of reasoning multiple thrombect-
omy devices have been evaluated for treating patients
* Correspondence: hgurm@umich.edu
1Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI,
USA
Tamhane et al. BMC Cardiovascular Disorders 2010, 10:10
http://www.biomedcentral.com/1471-2261/10/10
© 2010 Tamhane et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.with STEMI. Studies evaluating these devices have been
small and underpowered for clinical endpoints and have
demonstrated disparate results. Further, there are major
differences in thrombectomy devices and the results
obtained with one class of devices may not apply to all
devices. Prior meta-analyses evaluating the impact of
thrombectomy devices have combined studies of throm-
bectomy devices with those evaluating emboli protection
devices (EPDs) and have failed to establish the utility or
lack thereof of thrombectomy in patients with STEMI
[5-7].
The purpose of this meta-analysis was to systemati-
cally evaluate currently available data comparing throm-
bectomy followed by PCI with conventional PCI alone
in patients with acute STEMI and to assess for differ-
ences if any between the various types of thrombectomy
devices.
Methods
We performed a computerized search to identify rele-
vant articles from 1996 through December 2009 using
MEDLINE (National Library of Medicine, Bethesda,
Maryland), Google Scholar (Google Inc., Mountain
View, California), Embase, ISI Web of Knowledge, Cur-
rent Contents, International Pharmaceutical Abstracts
databases, and the Cochrane Central Register of Con-
trolled Trials. For MEDLINE we used the modified
Robinson and Dickersin strategy as described by Biondi
Zoccai et al [8] using the keywords “thrombectomy”,
“STEMI”, “ thrombus aspiration”, “ randomized” and “
PCI”. Abstract lists from the 2005 through 2009 scienti-
fic meetings of the American Heart Association, the
American College of Cardiology, the European Society
of Cardiology, published review articles, editorials, and
internet-based sources of information (http://www.cardi-
osource.com, http://www.tctmd.com, http://www.crton-
line.org, http://www.theheart.org, http://www.medscape.
com) were reviewed.
A study was included if it randomized patients with
STEMI to aspiration thrombectomy prior to PCI or con-
ventional PCI and provided information on 30-day out-
comes. Data was independently abstracted by two
reviewers (UT, IH) and disagreements were resolved by
consensus. Reviewers were not blinded to study authors
or outcomes. Attempt was made to retrieve the data
from the original source in unpublished studies. Since
no original data could be obtained in these studies, data
was retrieved from earlier published meta-analysis [6].
Baseline demographic, clinical and angiographic charac-
teristics including mean age of patients enrolled, percent
of male participants, patients with diabetes mellitus,
patients undergoing rescue PCI, proportion of patients
with anterior wall STEMI, use of platelet glycoprotein
IIb/IIIa receptor inhibitors, and mean symptom to
balloon time were recorded for each study. The specific
t y p eo ft h et h r o m b e c t o m yd e v i c eu s ei ne a c hs t u d yw a s
recorded and devices were subcategorized based on the
underlying mechanism into one of the three types
(mechanical, manual, or vacuum) as previously reported
[9].
We also assessed trial quality by evaluating specific
elements of study design (i.e. concealment of allocation
during randomization, intention to treat analysis and
blinded assessment of outcome measures), but did not
use a quality score given the limitations inherent to
such an approach [10].
Endpoints
Primary clinical endpoints included death, stroke, tar-
get vessel revascularization (TVR) and reinfarction.
The composite endpoint point of major adverse cardiac
events (MACE) at 30 days was not evaluated due to
differences in definitions used in the selected studies.
Myocardial perfusion was assessed by using angio-
graphic and electrocardiographic measures. ST resolu-
tion was defined as per the study definition. Most
studies defined ST resolution as more than 70% resolu-
tion in ST score [11] (defined as the sum of ST seg-
ment elevation in the leads V1 to V6, I, and aVL for
anterior and II, III, aVF, and V5 to V6 for non-anterior
infarctions). Single lead ST segment resolution by com-
paring the most prominent ST segment deviation was
used in the REMEDIA trial and by Antoniucci et al
[12,13]. Angiographic efficacy endpoints included post
procedural rates of thrombolysis in myocardial infarc-
tion (TIMI) grade 3 flow, and myocardial blush grade
(MBG).
MBG has been defined previously [14] as follows: 0,
no myocardial blush or contrast density; 1, minimal
myocardial blush or contrast density; 2, moderate myo-
cardial blush or contrast density but less than that
obtained during angiography of a contralateral or ipsilat-
eral non-infarct-related coronary artery; and 3, normal
myocardial blush or contrast density, comparable with
that obtained during angiography of a contralateral or
ipsilateral non-infarct-related coronary artery. When
myocardial blush persisted ("staining”), this phenomenon
suggested leakage of contrast medium into the extravas-
cular space and is graded 0. The angiographic endpoints
w e r ei n d e p e n d e n t l ya n a l y z e da tc o r el a b s .O ft h e1 3
trials that recorded MBG, 9 trials [11,12,15-21] used the
densitometry classification described by Van’t Hof et al
[14]. Two studies [22,23] utilized the dynamic method
described by Gibson et al [3], while the remaining 2 stu-
dies [24,25] did not specify the exact method used. The
authors had full access to the data and take responsibil-
ity for its integrity. All authors have read and agree to
the manuscript as written.
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From each trial, results were organized into a two-by-
two table to permit calculation of effect sizes for aspira-
tion thrombectomy in comparison with conventional
PCI in regards to each outcome. Data on the results
were collected on an “intention-to-treat” basis. When
the outcome did not occur in both groups, we were
unable to calculate effect sizes due to the empty cells
and data were excluded from that particular trial. Conti-
nuity correction was performed when an event did not
occur in one group. We used fixed-effects and random-
effects models to produce across-study summary odds
ratios (OR) with 95% confidence intervals. Since there
was significant heterogeneity for some of the endpoints,
the random-effects models are preferentially reported
for the entire group although fixed effect models gave
similar results. To assess the effect of individual studies
on the summary estimate of effect, we did an influence
analysis, in which the pooled estimates were recalculated
omitting one study at a time. Subgroup analysis sug-
gested that most of the heterogeneity could be explained
by disparate results with different device classes. There
was significant difference in trial size within subgroups
and to avoid undue influence of small trials, and given
lack of heterogeneity for most endpoints, Mantel-Haens-
zel fixed effect models are preferentially reported for the
subgroups although random effect models gave similar
results [26]. All p values were 2-tailed, with statistical
significance set at 0.05. Heterogeneity was assessed by
means of Cochrane Q heterogeneity test and considered
significant when p value was <0.10 [27]. Publication bias
was assessed by plotting a funnel plot and calculating
the rank order correlation [28] and Eggers test of inter-
cept [29]. We also calculated fail-safe N, using Rosen-
berg’s and Orwin’s method [30-32].
All analyses were performed using Comprehensive
Meta-Analysis software, version 2.0 (Biostat, Englewood,
New Jersey).
Results
A total of 330 citations published between January
1990 and December 2009 were screened (Figure 1).
Studies, which compared the two strategies without
randomization [33-35] or studies prospectively enrol-
ling consecutive patients for aspiration thrombectomy
were excluded [36-38]. Two randomized trials were
excluded as they compared two different types of
thrombus aspiration devices [39,40]. Of the remaining
20 trials, three were excluded since they did not pro-
vide angiographic or mortality data [41-43]. Our meta-
analysis thus included 17 trials that randomized
patients with STEMI to thrombectomy versus conven-
tional PCI. Of these, 14 had been published in peer-
reviewed journals [11-13,15-23,44,45] while two had
been published only as an abstract with information on
limited endpoints [25,46]. PIHRATE trial [24] was pre-
sented at Transcatheter Cardiovascular Therapeutics
meeting and the data was obtained from http://www.
tctmd.com and http://www.crtonline.org. A total of
3,909 patients from 17 randomized controlled trials
constituted our final study population. The characteris-
tics of included trials and study population are shown
in Table 1. Eight trials used manual aspiration throm-
bectomy (MAT) while mechanical and vacuum devices
were used in five and four trials respectively. (Table 1).
The raw clinical and angiographic events in each arm
across the trials are listed in Table 2 and 3. Summary
odds ratios of clinical and angiographic endpoints gen-
erated using fixed and random effect models are listed
in Table 4.
Clinical endpoints
30-day mortality
Data on 30-day mortality were available in 3821 patients
(98%). Mortality in the trials ranged from 0 to 7% in the
thrombectomy arm and 0 to 7% in the conventional PCI
arm. In the pooled estimate, 30-day death occurred in
44/1914 patients in the thrombectomy group and 50/
1907 patients in the conventional PCI group.
There was no difference in mortality between the two
strategies (OR 0.84, 95% CI 0.54-1.29, P = 0.42 Figure 2).
However subgroup analysis of trials studying manual,
mechanical and vacuum thrombus aspiration devices
showed a trend towards higher mortality with the use of
mechanical devices (OR 2.07, 95% CI 0.95-4.48, P =
0.07). MAT showed significant trend towards reduction
in mortality (OR 0.59, 95% CI 0.35-1.01, P = 0.05
Figure 3).
Stroke
Data on 30-day stroke were available in 2816 patients
(72%). The incidence of stroke ranged from the 0 to
2.1% in the thrombectomy arm and 0 to 2.1% in the
conventional PCI arm. Overall, stroke occurred in 14/
1403 patients in the thrombectomy group and 3/1413
patients in the conventional PCI group. There was a sig-
nificant increase in the likelihood of stroke with throm-
bectomy as compared with conventional PCI alone (OR
2.88, 95% CI 1.06-7.85, P = 0.04, P for heterogeneity =
0.97)
In subgroup analysis, there was a non-significant
increased likelihood of stroke due to use of any of these
devices compared to conventional PCI. (Vacuum devices
OR 5.05, 95% CI 0.24-106.37, P = 0.30, Mechanical
devices, OR 2.61, 95% CI 0.68-10.09, P = 0.16, and
MAT, OR 2.84, 95% CI 0.51-15.65, P = 0.23).
Target vessel revascularization (TVR) and Reinfarction
Data on 30-day TVR were available in 3041 patients
(77.8%). The incidence of TVR ranged from the 0 to
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conventional PCI arm. Overall, TVR occurred in 35/
1521 patients in the thrombectomy group and 36/1520
patients in the conventional PCI group. There was no
significant difference in the likelihood of TVR with
thrombectomy as compared with conventional PCI
alone (OR 0.92, 95% CI 0.57-1.49, P = 0.73).
Data on 30-day reinfarction were available in 3365
patients (86.1%). The incidence of reinfarction ranged
from the 0 to 4.0% in the thrombectomy arm and 0 to
4.0% in the conventional PCI arm. Overall, reinfarction
occurred in 12/1684 patients in the thrombectomy
group and 21/1681 patients in the conventional PCI
group. There was a non-significant decrease in the like-
lihood of reinfarction with thrombectomy as compared
with conventional PCI alone (OR 0.59, 95% CI 0.29-
1.22, P = 0.16).
Angiographic end points
Post procedural MBG
Data on post procedural myocardial blush were available
in 13 trials. One trial reported patients with MBG 0-1,
while twelve reported MBG 3 data.
Post procedural MBG 0-1
Data on post procedural MBG 0-1 were available in
2744 patients (70.2%). The rate of post procedural MBG
0-1 observed in the trials ranged from 0 to 45% in the
thrombectomy arm and 7 to 55% in the conventional
PCI arm. Overall, post procedural MBG 0-1 occurred in
308/1372 patients in the thrombectomy group and 428/
1372 patients in the conventional PCI group (OR 0.51,
95% CI 0.32-0.82, P = 0.005 Figure 4).
Post procedural MBG 3
Post procedural MBG 3 was available in 3039 patients
(77.7%). The rate of post procedural MBG 3 achieved in
Figure 1 Flow diagram depicting the selection of studies included in the meta-analysis.
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Svilaas, 2008 AIMI, 2006 DEAR-MI, 2006 Kaltoft, 2006
Thrombectomy Control Thrombectomy Control Thrombectomy Control Thrombectomy Control
Number of patients in each arm 535 536 240 240 74 74 108 107
Male (%) 68 73 76 74 84 76 76 80
Age, years (mean ± SD) 63 ± 13 63 ± 13 60 60 57 ± 13 59 ± 14 65 ± 11 63 ± 13
Diabetes (%) 11 13 17 16 21 15 8 6
Glycoprotein IIb/IIIa inhibitor use (%) 93 90 95 94 100 100 96 93
Anterior MI* (%) 43 43 39 37 42 51 46 43
Mean symptom to Balloon time
(minutes)
190
a 185
a 306
b 300
b 206 199 242 208
Thrombus (%) 49 44 65
c 58
c NA NA 69 79
Follow up duration, days 30 30 30 30 30 30 30 30
Device Export Angiojet Pronto Rescue
Mechanism Manual Mechanical Manual Vacuum
Total number of patients, (N) 1071 480 148 215
Primary outcome MBG Infarct size STR, MBG Myocardial salvage
De Luca, 2006 X-AMINE ST, 2005 REMEDIA, 2005 VAMPIRE, 2008
Thrombectomy Control Thrombectomy Control Thrombectomy Control Thrombectomy Control
Number of patients in each arm 38 38 100 101 50 49 180 175
Male (%) 71 55 76 73 90 78 80.6 77.7
Age, years (mean ± SD) 67 ± 14 65 ± 13 61 ± 13 62 ± 11 61 ± 13 60 ± 13 63.2 ± 11 63.5 ± 10
Diabetes (%) 24 18 25 18 22 18 23.3 29.9
Glycoprotein IIb/IIIa inhibitor use (%) 100 100 55 65 68 63 0 0
Anterior MI* (%) 97 100 54 50 40 51 50 52
Mean symptom to Balloon time
(minutes)
432 456 251 264 274 300 376 426
Thrombus (%) 100 100 100 100 58 55 NA NA
Follow up duration, days 180 180 180 180 30 30 240 240
Device Diver CE X-Sizer Diver CE TVAC Export
Mechanism Manual Mechanical Manual Vacuum Manual
Total number of patients, (N) 76 201 99 355 50
Primary outcome LV remodeling STR MBG, STR MBG
Export, 2005 Dudek, 2004 Antoniucci, 2004 NON STOP, 2004
Thrombectomy Control Thrombectomy Control Thrombectomy Control Thrombectomy Control
Number of patients in each arm 24 26 40 32 50 50 138 131
Male (%) NA NA NA NA 82 78 79 79
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Age, years (mean ± SD) NA NA NA NA 63 ± 13 66 ± 12 64 ± 12 66 ± 11
Diabetes (%) NA NA NA NA 18 16 NA NA
Glycoprotein IIb/IIIa inhibitor use (%) NA NA NA NA 98 98 NA NA
Anterior MI
¶ (%) NA NA NA NA 34 46 34 46
Mean symptom to Balloon time
(minutes) NA NA 258 236 234 264 NA NA
Thrombus (%) NA NA 100 100 NA NA NA NA
Follow up duration, days NA NA 90 90 30 30 NA NA
Device Export Rescue Angiojet Rescue
Mechanism Manual Vacuum Mechanical Vacuum
Total number of patients (N) 50 72 100 269
Primary outcome STR TIMI, cTFC, tMPG, STR STR NA
Napodano, 2003 Beran, 2002 Chevalier, 2008 EXPIRA, 2009
Thrombectomy Control Thrombectomy Control Thrombectomy Control Thrombectomy Control
Number of patients in each arm 46 46 30 31 120 129 88 87
Male (%) 83 72 73 77 80.8 81.4 64.7 55.1
Age, years (mean ± SD) 61 ± 11 64 ± 12 56 ± 10 54 ± 10 59.2 ± 13 61.2 ±
13
66.7 ± 14 64.6 ± 13
Diabetes (%) 13 13 17 13 16.7 13.2 22.7 18.4
Glycoprotein IIb/IIIa inhibitor use (%) 43 41 73 68 65.8 69.8 100 100
Anterior MI
¶ (%) 39 44 35 35 49.2 55.8 0 0
Mean symptom to Balloon time
(minutes)
238
b 204
b 291 279 321.7 271.4 408 456
Thrombus (%) 100 100 100 100 NA NA 100 100
Follow up duration, days 30 30 30 30 30 30 270 270
Device X-Sizer X-Sizer Export Export
Mechanism Mechanical Mechanical Manual Manual
Total number of patients, (N) 92 61 249 175
Primary outcome MBG cTFC STR, MBG MBG, STR
PIHRATE, 2007
Thrombectomy Control
Number of patients in each arm 102 94
Male (%) 79 81
Age, years (mean ± SD) 61 ± 10 58 ± 10
Diabetes (%) 12 10
Glycoprotein IIb/IIIa inhibitor use (%) 62 63
Anterior MI
¶ (%) NA NA
Mean symptom to Balloon time
(minutes)
195 206
Thrombus (%) 70 70
Follow up duration, days 180 180
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arm and 13% to 59% in the conventional PCI arm.
Overall, post procedural MBG 3 occurred in 730/1526
patients in the thrombectomy group and 486/1513
patients in the conventional PCI group. Patients in the
thrombectomy group were more likely to achieve post
procedural MBG 3 compared to those undergoing con-
ventional PCI (OR 2.42, 95% CI 1.63-3.61, P < 0.001
Figure 5).
In subgroup analysis the beneficial impact of throm-
bectomy on MBG 3 was seen in patients undergoing
thrombectomy by vacuum device (OR 3.01, 95% CI
1.98-4.60, P < 0.001) or by MAT (OR 2.30, 95% CI 1.90-
2.79, P < 0.001) but not in those treated with mechani-
cal devices (OR 1.06, 95% CI 0.78-1.45, P = 0.70).
Post procedural TIMI 3 flow
Data on post procedural TIMI 3 flow were available in
3807 patients (97.4%). The rate of post procedural TIMI
3 flow achieved in the trials ranged from 77 to 100% in
the thrombectomy arm and 63 to 100% in the conven-
tional PCI arm. Overall, post procedural TIMI 3 flow
occurred in 1616/1826 patients in the thrombectomy
group and 1533/1806 patients in the conventional PCI
group. There was an increased likelihood of achieving
post procedural TIMI 3 flow with thrombectomy com-
pared to conventional PCI (OR 1.41, 95% CI 1.10-1.81,
P = 0.007 Figure 6).
In subgroup analysis the beneficial impact of throm-
bectomy on post procedural TIMI 3 flow was seen in
patients undergoing thrombectomy by MAT (OR 1.50,
95% CI 1.17-1.92, P = 0.001) or by vacuum device (OR
1.49, 95% CI 0.99-2.23, P = 0.05) but not in those trea-
ted with mechanical devices (OR 0.79, 95% CI 0.43-1.45,
P = 0.45).
Electrocardiographic end point
70%",1,0,2,0,0pc,0pc,0pc,0pc>Post procedural ST-segment
resolution>70%
Data on post procedural ST-segment resolution>70%
were available in 2994 patients (76.6%). The post proce-
dural ST-segment resolution>70% achieved in the trials
ranged from 23 to 90% in the thrombectomy arm and
12 to 72% in the conventional PCI arm. Overall, post
procedural ST-segment resolution>70% occurred in 923/
1500 patients in the thrombectomy group and 715/1494
patients in the conventional PCI group.
There was a significant increase in the likelihood of
achieving post procedural ST-segment resolution>70%
with thrombectomy as compared with conventional PCI
(OR 2.30, 95% CI 1.64-3.23, P < 0.001, Figure 7).
In subgroup analysis the benefit was seen across all
three types of thrombectomy devices (MAT OR 1.95,
95% CI 1.62-2.34, P < 0.001, vacuum devices OR 1.80,
95% CI 1.01-3.18, P = 0.05, and mechanical devices OR
1.40, 95% CI 1.02-1.91, P = 0.04).
There was no evidence of publication bias for the var-
ious endpoints like 30-day death (figure 8) and myocar-
dial blush grade 3 (figure 9) on formal testing.
The calculated fail-safe N for a MBG 3 was 250. This
means that 250 ‘null’ studies would be needed in order
for the combined 2-tailed p-value to exceed 0.05. Calcu-
lation of Orwin’s fail-safe N, assuming a mean odds
r a t i oo f0 . 7 5i nt h em i s s i n gs t u d i e sw a s2 8 ,s u g g e s t i n g
that 28 studies with a mean odds ratio of 0.75 would be
needed to nullify the results.
To assess the effect of individual studies on the sum-
mary estimate of effect, we performed a sensitivity ana-
lysis, in which the pooled estimates for the primary
endpoint were recalculated omitting one study at a time,
but this did not alter the results.
Discussion
In this meta-analysis of seventeen randomized controlled
trials, we found that compared with conventional PCI,
thrombectomy devices are associated with an overall
improvement in surrogate endpoints of myocardial reper-
fusion like STR and MBG. However, this may not be a
“class effect” of thrombectomy and may vary significantly
by the device used. Moreover, there appears to be a trend
towards a survival benefit with the use of MAT while
vacuum devices had a neutral effect and mechanical
devices demonstrated a trend towards increasing mortality.
The use of thrombectomy devices however was asso-
ciated with an increased risk of stroke. While it is plau-
sible that some of the strokes are caused by
embolization of aspirated thrombus and occur at time
Table 1: Baseline characteristics of studies included in the meta-analysis (Continued)
Device Diver CE
Mechanism Manual
Total number of patients, (N) 196
Primary outcome STR
*In the studies with missing anterior MI rate, patients with left anterior descending artery as culprit artery were considered to have anterior MI; a = median;
NA = Not available. b = time from symptom onset to emergency department (ED) plus time from ED to randomization; MBG = Myocardial blush grade;
cTFC = Corrected TIMI frame count; tMPG = TIMI myocardial perfusion grade; STR = ST-segment resolution; TIMI = Thrombolysis in myocardial infarction grade
flow; c = Grade 4 or 5
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Study/Author Death Stroke Re-infarction Target vessel revascularization
Thrombectomy Control Thrombectomy Control Thrombectomy Control Thrombectomy Control
Svilaas 2% 4% 0% 0% 1% 2% 5% 6%
11 21 0 0 4 10 24 31
AIMI 5% 1% 1.7% 0.8% 0% 0% 2% 0.4%
1 1 24200 5 1
DEAR-MI 0% 0% 0% 0% 0% 0% 1.4% 0%
000000 1 0
Kaltoft 0% 1% 1.9% 0% 0% 1%
0 1 2 0 0 1 N/A N/A
De Luca 0% 5% 0% 0% 3% 0%
0 2 1 0 N/A N/A
X-AMINE 4% 4% 2% 0% 1% 3% 2% 0%
S T 442013 2 0
REMEDIA 6% 6% 2.1% 2.1% 4% 4% 2.1% 2.1%
331122 1 1
VAMPIRE 1% 1% 0% 1% 0% 1%
1 1 N/A N/A 0 1 0 1
EXPORT 0% 4%
0 1 N/A N/A N/A N/A N/A N/A
Dudek
N/A N/A N/A N/A N/A N/A N/A N/A
Antoniucci 0% 0% 2% 0% 0% 0% 0% 0%
001000 0 0
NON 1% 1.5%
STOP 2 2 N/A N/A N/A N/A N/A N/A
Napodano 7% 7% 0% 0% 4% 4% 0% 0%
330022 0 0
Beran 7% 3% 0% 3%
2 1 N/A N/A N/A N/A 0 1
Chevalier 3% 4% 2% 0% 3% 1% 0% 0%
452031 0 0
EXPIRA 0% 1% 2% 0% 0% 0% N/A N/A
012000
PIHRATE 3% 3% N/A N/A 0% 1% 2% 1%
33 01 2 1
N/A = not available
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Study/Author MBG 0-1 MBG 3 ST segment resolution Post procedural TIMI 3 flow
Thrombectomy Control Thrombectomy Control Thrombectomy Control Thrombectomy Control
Svilaas 17% 26% 46% 32% 57% 44% 86% 83%
84 129 224 158 275 219 431 409
AIMI 45% 36% 27% 32% 60% 68% 91% 97%
105 85 63 75 105 111 213 228
DEAR-MI 0% 7% 88% 43% 68% 50% 89% 78%
0 5 65 32 50 37 66 58
Kaltoft N/A N/A N/A N/A 23% 22% 89% 88%
22 20 93 91
De Luca N/A N/A 37% 13% 82% 55% 79% 68%
14 5 31 21 30 26
X-AMINE ST 25% 25% 31% 30% 68% 53% 96% 89%
23 23 29 28 61 50 96 90
REMEDIA 32% 55% N/A N/A 63% 37% 77% 63%
16 27 29 18 37 31
VAMPIRE 17% 37% 46% 20% N/A N/A 88% 81%
30 63 82 35 155 137
EXPORT N/A N/A 63% 42% 50% 12% 96% 81%
15 11 12 3 23 21
Dudek N/A N/A 55% 38% 68% 25% 85% 86%
22 12 27 8 34 27
Antoniucci N/A N/A N/A N/A 90% 72% 100% 100%
45 36 50 50
NON STOP N/A N/A N/A N/A N/A N/A 94% 91%
130 119
Napodano 15% 46% 72% 37% 83% 52% 94% 96%
7 2 13 31 73 82 4 4 3 4 4
Beran N/A N/A N/A N/A 83% 52% 90% 84%
19 12 27 26
Chevalier 28% 32% 36% 25% 74% 65% 82% 77%
33 41 43 33 88 84 98 99
EXPIRA 12% 40% 70% 29% 80% 38% N/A N/A
10 34 62 25 70 33
PIHRATE N/A N/A 76% 59% 50% 41% 88% 82%
78 55 51 39 90 77
N/A = not available
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Endpoint Summary odds ratio (random-effect
model)
Summary odds ratio (fixed-effect
model)
P-value for
Heterogeneity
Death 0.84 (95% CI 0.54-1.29) 0.84 (95% CI 0.54-1.29) 0.66
Stroke 2.88 (95% CI 1.06-7.85) 2.88 (95% CI 1.06-7.85) 0.97
Re-infarction 0.59 (95% CI 0.29-1.22) 0.59 (95% CI 0.29-1.22) 0.80
Target vessel Revascularization 0.92 (95% CI 0.57-1.49) 0.92 (95% CI 0.57-1.49) 0.57
Myocardial blush grade 0-1 0.51 (95% CI 0.32-0.82) 0.64 (95% CI 0.54-3 0.77) <0.001
Myocardial blush grade 3 2.42 (95% CI 1.63-3.61) 1.95 (95% CI 1.67-2.28) <0.001
ST elevation resolution >70% 2.30 (95% CI 1.64-3.23) 1.79 (95% CI 1.53-2.08) <0.001
Thrombolysis in myocardial infarction
(TIMI) flow-3
1.41 (95% CI 1.10-1.81) 1.39 (95% CI 1.14-1.70) 0.21
Figure 2 The Forest plot of odds ratios of 30-day mortality. Sizes of data markers are proportional to the weight of each study in the meta-
analysis. Horizontal bars = 95% CI.
Figure 3 The Forest plot of odds ratios of 30-day mortality for manual aspiration therapy (MAT), mechanical and vacuum devices.
Sizes of data markers are proportional to the weight of each study in the meta-analysis. Horizontal bars = 95% CI.
Tamhane et al. BMC Cardiovascular Disorders 2010, 10:10
http://www.biomedcentral.com/1471-2261/10/10
Page 10 of 17of PCI, lack of time to event data prevented us from for-
mally assessing this hypothesis. Even with MAT, the risk
of stroke even though statistically not significant,
appears clinically relevant and cannot be ignored.
Assuming similar base line risk, our data would suggest
that treating 1000 patients with MAT would be asso-
ciated with saving 14 lives (95% CI 0 to 29, P = 0.05)
with a stroke occurring in 5 patients (95% CI -2 to 12, P
= 0.20). These calculations are influenced by the base-
line risk which in general tends to be lower in clinical
trial and the absolute mortality reduction could be lar-
ger in patients with a higher baseline mortality hazard
[47,48].
ST-elevation myocardial infarction is characterized by
thrombus formation and occlusion of the infarct related
artery (IRA). Angiographic evidence of thrombus in the
IRA is associated with poor in-hospital outcomes
[49,50]. Conventional PCI while attempting to open the
occlusion is more likely to dislodge the thrombus down-
stream causing distal embolization and microvascular
obstruction [51] and contribute to “no reflow phenom-
enon” [52]. Distal embolization has been found to occur
in 15% of patients undergoing conventional PCI and is
associated with reduced microvascular reperfusion of
the myocardium, increased infarct size and higher long
term mortality [53]. Reduced myocardial reperfusion can
be tested by myocardial salvage index-defined as the
proportion of jeopardized myocardium that was salvaged
(measured by 99mTc-sestamibi scintigraphy), post pro-
cedural myocardial perfusion grades and persistence of
ST elevation after PCI. Myocardial salvage index is an
independent predictor of long-term prognosis [54] and
Figure 4 The Forest plot of odds ratios of post procedural MBG 0-1. Sizes of data markers are proportional to the weight of each study in
the meta-analysis. Horizontal bars = 95% CI.
Figure 5 The Forest plot of odds ratios of post procedural MBG 3. Sizes of data markers are proportional to the weight of each study in the
meta-analysis. Horizontal bars = 95% CI.
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Page 11 of 17has been shown to closely correlate with myocardial
perfusion grade [55] and with resolution of ST-segment
elevation on electrocardiography [56].
Myocardial blush grade (MBG) and ST resolution
have emerged as valid surrogates of adequate reperfu-
sion and poorer MBG has been consistently associated
with increased infarct size, lower left ventricular func-
tion and higher long-term mortality [14,57]. Similarly,
persistent ST elevation after PCI is associated with
increased infarct size, decreased left ventricular function
and higher mortality [58,59]. Poli et al [60] suggested
that a combined analysis of MBG and STR allows a
real-time grading of microvascular reperfusion of the
infarct area and predicts the time-course and magnitude
of LV functional recovery. They found that patients,
who had neither significant MBG nor ST resolution,
had poor early and late left ventricular functional
recovery.
Recently Svilaas et al have shown a significant rela-
tionship between electrocardiographic and myocardial
variables of reperfusion and the rate of deaths and
major adverse events [20]. Therefore, thrombectomy
Figure 6 The Forest plot of odds ratios of post procedural TIMI 3 flow. Sizes of data markers are proportional to the weight of each study
in the meta-analysis. Horizontal bars = 95% CI.
Figure 7 The Forest plot of odds ratios of post procedural ST-segment resolution > 70%. Sizes of data markers are proportional to the
weight of each study in the meta analysis. Horizontal bars = 95% CI.
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Page 12 of 17devices were developed in an attempt to ameliorate
the adverse effects of increased thrombus burden and
its subsequent sequelae of decreased myocardial reper-
fusion. Our meta-analysis showed an overall benefit in
the markers of myocardial reperfusion (MBG and
STR) in thrombectomy devices consistent with earlier
meta-analysis [5]. However, within the thrombectomy
g r o u pM A Tw a sm o r el i k e l yt ob eb e n e f i c i a lc o m p a r e d
to mechanical devices in achieving these endpoints.
Specific features of the device and its shortcomings
may play a role in explaining the differing results
between manual and mechanical devices on clinical and
angiographic endpoints. The significant rigidity of the
mechanical catheters e.g. X-sizer, Angiojet decrease
their ability to cope with tortuosity and excessive calcifi-
cation proximal to the culprit lesion. Their large profile
prevents crossing of tight lesions and limits its use with
arteries with reference diameter >2.5 mm [9,61]. The
Figure 8 Funnel plot for the endpoint of 30-day death.
Figure 9 Funnel plot for the endpoint of myocardial blush grade 3.
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Page 13 of 17larger profiles of these devices have the potential of
inducing distal embolization and may paradoxically
increase infarct size as seen in some studies [17,45].
The hydraulics of the various thrombectomy devices
and the role of negative pressure developed in these
devices for thrombus extraction on vessel injury is
potentially important. In the Angiojet rheolytic throm-
bectomy system the pressurized saline jets delivered to
catheter tip travel retrograde at the speed of 339 miles/
hour creating a near perfect vacuum (-600 mm Hg) at
the distal catheter tip for thrombus aspiration [62]. In
the vacuum devices like Rescue [45] and the TVAC
[35], continuous suction of 0.84 and 0.9 atmospheres
respectively is applied. These high negative pressures
may cause vessel collapse and injury in vessels with
small caliber. Further, the mechanical devices incorpo-
rate thrombus fragmentation and aspiration and it is
possible that a significant proportion of the fragmented
thrombus embolizes and thus causes microvasculature
injury [63]. Further, it is not clear if operator experience
can explain some of the differences. The more sophisti-
cated mechanical devices have a prolonged learning
c u r v et h a ti su n l i k e l yt oa p p l yt ot h em o r es i m p l e r
MAT.
In comparison, the manual devices have a lower pro-
file, are easy to operate, have short learning curve, less
bulky and easy to set up by the catheterization labora-
tory staff and unlikely to add delay to perfusion of the
occluded vessel. These differences likely explain the con-
flicting impact on survival seen with these devices.
The results of our meta-analysis, involving 3909
patients differ from those of the earlier work. In the
meta-analysis by Deluca and colleagues (2231 patients)
there was a trend towards higher mortality with throm-
bectomy (2.7% versus 2.1%, OR 1.28, 95% CI 0.69-2.38,
P = 0.43). A similar trend was present in a meta-analysis
by Burzotta et al and Kunadian et al [7] involving about
1700 and 1500 patients respectively. Our meta-analysis
incorporated larger studies with more patients under-
going MAT, did not include EPDs and our findings are
therefore more likely extant. On the other hand, our
results corroborate the results of prior studies regarding
the beneficial impact of thrombectomy devices on post
procedural MBG 3 and TIMI 3 flow [6]. In a meta ana-
lysis of 9 trials Deluca et al [64] showed a significant
improvement in mortality with the use of manual
aspiration devices. The results of this study are similar
to our study in terms of improvement in myocardial
perfusion. While the directionality of the results is simi-
lar, our results did not achieve statistical significance.
This may relate to differences in statistical tests use.
Recently a pooled analysis of 11 trials and 2674 patients
by Burzotta et al [65] based on individual patient-data,
w i t hm e d i a no n ey e a rf o l l o wu ps h o w e dt h a ta l l o c a t i o n
to thrombectomy was associated with significantly lower
all-cause mortality (P = 0.049). In the manual throm-
bectomy group, Kaplan-Meier analyses at the longest
follow-up available showed that thrombectomy was
associated with significantly fewer deaths (log-rank P =
0.011).
Our study results highlight the similar observations
made by Bavry et al [66] regarding the increased inci-
dence of stroke with the use of manual and mechanical
aspiration devices.
The results of our meta-analysis would suggest that
when thrombectomy is performed in patients under-
going PCI, the best outcome is seen with the “gentler”
manual aspiration thrombectomy (MAT). Ideally, one
would like to validate the results of our meta-analysis in
large trials comparing manual and mechanical devices
using hard clinical endpoints. Such a trial is however
unlikely given the logistics and cost involved. On the
other hand, it would be helpful to evaluate the survival
benefits if any of manual aspiration over routine PCI in
larger studies.
Limitations
The limitations of our meta-analysis are those inherent
to all meta-analyses, and they include publication bias
(although tested non-significant in our study) and the
difficulties in comparing the results because of the dif-
ferent study populations, study designs and reporting
m e t h o d sa sw e l la st h ea b s e n c eo fi n d i v i d u a lp a t i e n t
data, which prohibits adjustment for confounding fac-
tors [67]. Data on clinical endpoints like 30-day mortal-
ity, stroke, TVR, reinfarction and angiographic
endpoints like MBG 0-1, 3 were not available in some
trials. Data on cardiac remodeling e.g. left ventricular
ejection fraction (LVEF), left ventricular volumes and
diameters were not availablei nm o s tt r i a l s .S i x - m o n t h
data was available only in two trials and hence long-
term outcomes could not be studied. Six of our studies
included were not published; however, the results of
sensitivity analysis did not show an impact of publica-
tion status on the study results. The event rates of clini-
cal endpoints like death, myocardial infarction, and
stroke are low in patients undergoing primary PCI as
seen in large PCI registry [68]. Even with the approach
of a meta-analysis the number of endpoints is low. Our
meta-analysis may not be powered to detect significant
differences with respect to these endpoints.
In addition, our results cannot supplant a large ade-
quately powered randomized clinical trial.
Conclusion
Our meta-analysis suggests a beneficial impact of
thrombectomy devices on surrogate endpoints like MBG
and STR. These devices have a differing impact on hard
Tamhane et al. BMC Cardiovascular Disorders 2010, 10:10
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Page 14 of 17clinical endpoints with an improvement seen with MAT
and worsening outcome with mechanical devices. These
data suggest a need for further large clinical trials evalu-
ating the utility of MAT in patients undergoing primary
PCI.
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